CA2310510C - Method for identifying and inhibiting functional nucleic acid molecules in cells - Google Patents
Method for identifying and inhibiting functional nucleic acid molecules in cells Download PDFInfo
- Publication number
- CA2310510C CA2310510C CA002310510A CA2310510A CA2310510C CA 2310510 C CA2310510 C CA 2310510C CA 002310510 A CA002310510 A CA 002310510A CA 2310510 A CA2310510 A CA 2310510A CA 2310510 C CA2310510 C CA 2310510C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- rna
- nucleic acid
- interest
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 97
- 102000039446 nucleic acids Human genes 0.000 title claims description 59
- 108020004707 nucleic acids Proteins 0.000 title claims description 59
- 150000007523 nucleic acids Chemical class 0.000 title claims description 59
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 209
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 127
- 239000013598 vector Substances 0.000 claims abstract description 88
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 63
- 230000008685 targeting Effects 0.000 claims abstract description 47
- 102000053642 Catalytic RNA Human genes 0.000 claims abstract description 44
- 108090000994 Catalytic RNA Proteins 0.000 claims abstract description 44
- 108091092562 ribozyme Proteins 0.000 claims abstract description 44
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 39
- 230000007017 scission Effects 0.000 claims abstract description 39
- 108090000621 Ribonuclease P Proteins 0.000 claims abstract description 33
- 102000004167 Ribonuclease P Human genes 0.000 claims abstract description 33
- 241000588724 Escherichia coli Species 0.000 claims abstract description 31
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 15
- 230000035899 viability Effects 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 152
- 230000014509 gene expression Effects 0.000 claims description 112
- 102000004169 proteins and genes Human genes 0.000 claims description 106
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 55
- 108020004999 messenger RNA Proteins 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 108020004566 Transfer RNA Proteins 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 12
- 108020005544 Antisense RNA Proteins 0.000 claims description 10
- 239000003184 complementary RNA Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 7
- 230000002147 killing effect Effects 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
- 108020004418 ribosomal RNA Proteins 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 claims description 4
- 241000202934 Mycoplasma pneumoniae Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000228197 Aspergillus flavus Species 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000588770 Proteus mirabilis Species 0.000 claims description 3
- 241000588767 Proteus vulgaris Species 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 241001312524 Streptococcus viridans Species 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- 230000003833 cell viability Effects 0.000 claims description 3
- 229940007042 proteus vulgaris Drugs 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 108020000999 Viral RNA Proteins 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 229940095731 candida albicans Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 abstract description 32
- 125000003729 nucleotide group Chemical group 0.000 abstract description 32
- 239000000758 substrate Substances 0.000 abstract description 14
- 108700039887 Essential Genes Proteins 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 230000004071 biological effect Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 108020004513 Bacterial RNA Proteins 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 description 100
- 235000018102 proteins Nutrition 0.000 description 74
- 108020004414 DNA Proteins 0.000 description 60
- 230000000694 effects Effects 0.000 description 31
- 239000013612 plasmid Substances 0.000 description 25
- 239000005090 green fluorescent protein Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 16
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 16
- 230000004927 fusion Effects 0.000 description 16
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 15
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108010042653 IgA receptor Proteins 0.000 description 8
- 229930182555 Penicillin Natural products 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 8
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 231100000518 lethal Toxicity 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 229940049954 penicillin Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000023308 Acca Species 0.000 description 5
- 241000251131 Sphyrna Species 0.000 description 5
- 101150055766 cat gene Proteins 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 231100000225 lethality Toxicity 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 230000009643 growth defect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- -1 phosphorothioate diester Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000606697 Rickettsia prowazekii Species 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102000005497 Thymidylate Synthase Human genes 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940013390 mycoplasma pneumoniae Drugs 0.000 description 2
- 239000006225 natural substrate Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229940046939 rickettsia prowazekii Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- ALACEDPNJIAQMY-UHFFFAOYSA-N 1,3-dihydroxypyrimidine-2,4-dione Chemical compound ON1C=CC(=O)N(O)C1=O ALACEDPNJIAQMY-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241000207208 Aquifex Species 0.000 description 1
- 241000893512 Aquifex aeolicus Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000894010 Buchnera aphidicola Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000229118 Clostridium sp. MCF-1 Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical class N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101710137619 DNA gyrase inhibitor Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001235200 Haemophilus influenzae Rd KW20 Species 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 244000132194 Lactobacillus helveticus subsp jugurti Species 0.000 description 1
- 235000005448 Lactobacillus helveticus subsp jugurti Nutrition 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241001492414 Marina Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000204051 Mycoplasma genitalium Species 0.000 description 1
- 241000432072 Mycoplasma pneumoniae M129 Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000605860 Prevotella ruminicola Species 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000589187 Rhizobium sp. Species 0.000 description 1
- 241001148569 Rhodothermus Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 101150054830 S100A6 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001135266 Salmonella enterica subsp. enterica serovar Berta Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000187433 Streptomyces clavuligerus Species 0.000 description 1
- 241000509474 Streptomyces flavovirens Species 0.000 description 1
- 241000187411 Streptomyces phaeochromogenes Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000192593 Synechocystis sp. PCC 6803 Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000520244 Tatumella citrea Species 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 244000000188 Vaccinium ovalifolium Species 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940126573 antibacterial therapeutic Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US976,220 | 1997-11-21 | ||
| US08/976,220 US6013447A (en) | 1997-11-21 | 1997-11-21 | Random intracellular method for obtaining optimally active nucleic acid molecules |
| US7985198P | 1998-03-30 | 1998-03-30 | |
| US60/079,851 | 1998-03-30 | ||
| PCT/US1998/024854 WO1999027135A2 (en) | 1997-11-21 | 1998-11-20 | Method for identifying and inhibiting functional nucleic acid molecules in cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2310510A1 CA2310510A1 (en) | 1999-06-03 |
| CA2310510C true CA2310510C (en) | 2007-04-17 |
Family
ID=26762503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002310510A Expired - Fee Related CA2310510C (en) | 1997-11-21 | 1998-11-20 | Method for identifying and inhibiting functional nucleic acid molecules in cells |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1032707A2 (de) |
| JP (1) | JP2001524317A (de) |
| AU (1) | AU732321B2 (de) |
| CA (1) | CA2310510C (de) |
| WO (1) | WO1999027135A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1034308A4 (de) * | 1997-12-04 | 2002-04-03 | Smithkline Beecham Corp | Verfahren zur herstellung conditionell exprimierten mutanten zellen mit hilfe von expriemirten antisense sequenzen |
| AU4186600A (en) * | 1999-03-31 | 2000-10-16 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferation drugs |
| GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
| GB9929744D0 (en) * | 1999-12-17 | 2000-02-09 | Univ Nottingham | Modifying micro-organisms |
| WO2001048239A2 (de) * | 1999-12-23 | 2001-07-05 | Xantos Biomedicine Ag | Screening-verfahren für nukleinsäuren |
| AU2008202554C1 (en) * | 2001-02-23 | 2011-07-07 | Dsm Ip Assets B.V. | Novel genes encoding novel proteolytic enzymes |
| US20130244905A1 (en) * | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| EP0638121B1 (de) * | 1992-04-28 | 1996-07-17 | Yale University | Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz |
| JPH08507203A (ja) * | 1992-12-04 | 1996-08-06 | イノーバー ラボラトリーズ，インコーポレイテッド | 調節可能な核酸治療およびそれらの使用方法 |
| WO1996018733A2 (en) * | 1994-12-14 | 1996-06-20 | Innovir Laboratories, Inc. | Ribozyme-mediated inactivation of leukemia-associated rna |
| WO1997010360A1 (en) * | 1995-09-13 | 1997-03-20 | Chiron Corporation | Method and construct for screening for inhibitors of transcriptional activation |
| US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
| WO1998006837A1 (en) * | 1996-08-16 | 1998-02-19 | Yale University | Phenotypic conversion of drug-resistant bacteria to drug-sensitivity |
| AU5927598A (en) * | 1997-01-23 | 1998-08-18 | Immusol Incorporated | Gene functional analysis and discovery using randomized or target-specific ribozyme gene vector libraries |
-
1998
- 1998-11-20 EP EP98959542A patent/EP1032707A2/de not_active Withdrawn
- 1998-11-20 CA CA002310510A patent/CA2310510C/en not_active Expired - Fee Related
- 1998-11-20 AU AU15323/99A patent/AU732321B2/en not_active Ceased
- 1998-11-20 JP JP2000522276A patent/JP2001524317A/ja active Pending
- 1998-11-20 WO PCT/US1998/024854 patent/WO1999027135A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU732321B2 (en) | 2001-04-12 |
| AU1532399A (en) | 1999-06-15 |
| WO1999027135A2 (en) | 1999-06-03 |
| JP2001524317A (ja) | 2001-12-04 |
| CA2310510A1 (en) | 1999-06-03 |
| EP1032707A2 (de) | 2000-09-06 |
| WO1999027135A3 (en) | 1999-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113646434B (zh) | 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法 | |
| EP3752647B1 (de) | Zellendatenschreiber und verwendungen davon | |
| Xu et al. | A CRISPR/Cas13-based approach demonstrates biological relevance of vlinc class of long non-coding RNAs in anticancer drug response | |
| Zeng et al. | Phosphate solubilization and gene expression of phosphate-solubilizing bacterium Burkholderia multivorans WS-FJ9 under different levels of soluble phosphate | |
| US6248525B1 (en) | Method for identifying essential or functional genes | |
| US20100212040A1 (en) | Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences | |
| US6013447A (en) | Random intracellular method for obtaining optimally active nucleic acid molecules | |
| US7524653B2 (en) | Small interfering RNA libraries and methods of synthesis and use | |
| Stumpf et al. | Polyphosphate kinase regulates error‐prone replication by DNA polymerase IV in Escherichia coli | |
| Lee et al. | Insertion-duplication mutagenesis in Streptococcus pneumoniae: targeting fragment length is a critical parameter in use as a random insertion tool | |
| CA2310510C (en) | Method for identifying and inhibiting functional nucleic acid molecules in cells | |
| Slechta et al. | Evidence that selected amplification of a bacterial lac frameshift allele stimulates Lac+ reversion (adaptive mutation) with or without general hypermutability | |
| US20020002278A1 (en) | Random intracellular method for obtaining optimally active nucleic acid molecules | |
| EP1184462A2 (de) | Identifizierung von Zielen für antimikrobielle Verbindungen | |
| US20020058287A1 (en) | Novel small nuclear RNA vectors and uses therefor | |
| US20040248101A1 (en) | Identification of novel antibacteria agents by screening the single-stranded DNA expression library | |
| Chetverin | Recombination in Bacteriophage Qβ and Its Satellite RNAs: Thein Vivoandin VitroStudies | |
| AU2011203213A1 (en) | Selection and Isolation of Living Cells Using mRNA-Binding Probes | |
| Ellis et al. | A multiplex CRISPR interference tool for virulence gene interrogation in an intracellular pathogen | |
| US20050136393A1 (en) | Oligodoxynucleotide (ODN) libraries, their use in screening for antibacterial agents, and catalytic ODN sequence for use as an antibacterial agent | |
| AU2008202162B2 (en) | Selection and Isolation of Living Cells Using mRNA-Binding Probes | |
| Delaleau et al. | Comprehensive mapping of transcription terminator Rho utilization (Rut) sites across the Bacillus subtilis genome | |
| Billingsley et al. | Nucleic Acid Hybridization Techniques and Neurotoxicity Assessment | |
| Winkler | Regulatory RNAs at the Heart of Sugar Metabolism: New Mechanisms and Novel Discoveries | |
| HK1079238B (en) | Selection and isolation of living cells using rna-binding probes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141120 |